الفهرس 
Introduction
Liver fibrosis in NASHOnly 14 pages are availabe for public view
 |  | from | 195 |  |  |
| | | from | 195 | | |
Abstract
BACKGROUND: Hyperlipidemic states such as nephrotic syndrome are associated with high incidence of fatty liver. In the current study; we evaluate the possible protective effect of Enalapril (Angiotensin converting enzyme inhibitor) and pravastatin (HMG-COA reductase inhibitors) on fatty liver in animal model of nephrotic syndrome. METHODS: 44 male Sprague-Dawley rats were divided into 2 groups: group (I) healthy control group, group (II) nephrotic group which was further subdivided into: (IIa) nephrotic group with no medication, (IIb) nephrotic group treated daily with enalapril, and (IIc) nephrotic group treated daily with pravastatin.After 12 weeks, kidney functions, liver functions blood lipid profile were done, also the liver and the kidney were subjected to pathological examinations. RESULTS: Enalapril treated group had significantly higher body weight (P <0.001) and serum albumin (P=0.03),with significant decrease in proteinuria (P <0.001) and SGPT (P=0.01), with insignificant effect on hyperlipidemia ,with also significant improvement on fatty liver pathology(P <0.001).Also, pravastatin treated group had significant decrease in hyperlpidemia(P <0.001), while body weight (P=0.89), serum albumin(P=0.61)., proteinuria (P=0.08) and SGPT showed no significant improvement (P=0.95).Also, pravastatin significant improvement in hepatic pathology (P <0.001),though less than enalapril . CONCLUSION: ACE inhibitors have beneficial protective effect on NASH .Also, pravastatin plays a significant protective role against hazardous effects of dyslipidemia such as NAFLD. The current work provides some evidence that they can be used safely, but more studies should be conducted to evaluate the long-term effects of statins on hepatic status.